Drugs / Trimer 4571
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06332339 | Mar 2024 → Nov 2026 expected | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05781542 | Apr 2023 → Oct 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT05828095 | Apr 2023 → Jan 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT05470400 | Aug 2022 → Jan 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT04985760 | Sep 2021 → Jan 2026 | HIV infectious disease | Madhu Chhanda Choudhary | Completed | No outcome recorded |
| Phase 1 | NCT04177355 | Jan 2020 → Nov 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trimer-4571 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05828095 ↗ |
| Known as | HIV-1 Trimer 4571 Vaccine | “HIV-1 Trimer 4571 Vaccine” NCT04985760 ↗ |
| Modality | Vaccine | “Investigational vaccine composed of Trimer 4571 100mcg, alum (aluminum hydroxide suspension) adjuvant 500mcg, and phosphate buffered saline diluent” NCT04985760 ↗ |
| Route | Intramuscular | “as a 1ml intramuscular injection at Day 0, Week 8 and Week 20” NCT04985760 ↗ |